BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
VANCOUVER, BC / ACCESSWIRE / December 2, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, announces the development of a sublingual thin-film oral dissolvable film (ODF) for Semaglutide, internally identified as BNT24005. This innovative product is intended to address limitations of existing administration methods for a therapeutic developed by Novo Nordisk, with the aim of improving patient accessibility and convenience. This product is currently under development and remains subject to regulatory review and approval.
Semaglutide: A Proven Therapeutic Leader
Semaglutide, developed by Novo Nordisk and marketed under brand names such as Ozempic® and Wegovy®, has revolutionized treatment for Type 2 diabetes and obesity. By mimicking glucagon-like peptide-1 (GLP-1), it enhances insulin secretion, reduces appetite, and slows gastric emptying, offering powerful tools for glycemic control and weight management.
In 2023, Semaglutide generated over $14 billion in revenue globally, reflecting surging demand for effective diabetes and obesity treatments (The Washington Post).
The BioNxt Advantage
Despite Semaglutide's success, its injectable format presents barriers, including needle anxiety and challenges with long-term adherence. BioNxt's sublingual thin-film technology, BNT24005, offers a novel delivery system that aims to reduce these hurdles, improving the overall patient experience.
Key benefits of the sublingual thin-film include:
Needle-Free Convenience: A painless and discreet alternative to injections.
Rapid Absorption: Direct sublingual delivery for faster therapeutic action.
Enhanced Bioavailability: Reduced enzymatic degradation compared to traditional oral routes.
Improved Patient Compliance: A portable, user-friendly format designed to encourage long-term adherence.
This next-generation delivery method has the potential to address unmet needs in diabetes and obesity care, aligning with global trends favoring patient-centric solutions.
Significant Market Opportunity
The global burden of diabetes and obesity underscores the growing need for innovative treatments. According to the International Diabetes Federation, over 537 million adults worldwide are living with diabetes, and the prevalence of obesity continues to rise.
Semaglutide's existing market success highlights the potential for innovative delivery systems. BioNxt aims to address patient challenges while adhering to stringent regulatory and intellectual property standards.
Strategic Development and Patent Positioning
BioNxt's thin-film innovation focuses on enhancing drug delivery methods without infringing on existing molecule patents. The product leverages a strategy centered on patentable administration improvements, respecting the intellectual property of Novo Nordisk.
BioNxt's Broader Pipeline of Innovations
The Semaglutide thin-film, BNT24005, is part of BioNxt's broader portfolio of advanced drug delivery technologies, targeting therapeutic areas such as neurodegenerative diseases, metabolic disorders, and other high-need markets. BioNxt's platforms include sublingual thin-films, transdermal patches, and enteric-coated oral tablets, all designed to enhance patient outcomes and healthcare accessibility.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablet)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements regarding the development, potential benefits, and commercialization of BioNxt's sublingual thin-film product for Semaglutide. These statements are based on current expectations and projections about future events but involve risks and uncertainties outside of the Company's control. Risks include challenges in obtaining regulatory approvals, potential intellectual property disputes or claims from third parties, and uncertainties associated with product development, manufacturing, and clinical validation. Additional risks include the potential for limited market acceptance of the sublingual thin-film technology and competitive pressures within the diabetes and obesity therapeutic sectors. Readers are cautioned that actual results may differ materially from those expressed in these forward-looking statements due to these and other factors. BioNxt Solutions Inc. undertakes no obligation to update forward-looking statements, except as required by applicable laws.
Trademarks: Trademarks Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S and are referenced in this document solely for informational and comparative purposes to contextualize the market landscape. BioNxt Solutions Inc. is neither affiliated with nor endorsed by Novo Nordisk A/S.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Holdings Inc. Announces the Acquisition of Harper Engineering Company22.1.2026 14:30:00 CET | Press release
WHITE PLAINS, NEW YORK / ACCESS Newswire / January 22, 2026 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has completed the acquisition of Harper Engineering Company ("Harper") for cash consideration of $250 million. Founded in 1968 by O.J. Harper, Harper Engineering is a leading manufacturer of mechanically engineered devices for aircraft interiors. The company holds a proprietary portfolio of latching and securing mechanisms used across multiple leading commercial aerospace platforms. Known for exceptional quality and on-time delivery, Harper consistently earns top recognition from its original equipment and aftermarket customers. The company employs approximately eighty-five team members across two facilities in the Seattle, Washington area. "Harper maintains well-established line-fit positions on several leading in-production aircraft, positioning the business to benefit from near-term growth in commercial build rates," said Dirkson Charles, Chief Executive Offi
GoodData Announces Launch of MCP Server to Let AI Execute Analytics End-to-End21.1.2026 10:00:00 CET | Press release
Combining MCP, analytics-as-code, and LLMs to automate analytics execution at software speed SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 21, 2026 / GoodData, a leader in AI analytics and decision intelligence, today announced the public launch of its MCP Server. As organisations adopt AI in analytics, most tools remain limited to query generation, leaving teams to manually manage metrics, dashboards and business logic. MCP Server moves AI beyond analysis, enabling governed, end-to-end analytics execution and delivering 10-50x faster time to value. The MCP Server is designed for AI developers, and BI and data teams who want to build and manage analytics faster with AI. It allows AI to build and operate analytics in the same way a skilled human team would, but faster and without operational bottlenecks. Using the Model Context Protocol (MCP), AI agents and large language models (LLMs) can connect directly to GoodData and execute analytics across the full lifecycle. They can wor
Kontent.ai Launches AI-Powered SEO and GEO Workflows to Cut Optimization Time by Up to 80% and Optimize Content for Search and Answer Visibility21.1.2026 08:00:00 CET | Press release
Kontent.ai today announced the launch of new agentic SEO and Generative Engine Optimization (GEO) workflows following early results that show organizations reducing the time required to audit and optimize content performance by up to 80 percent while improving organic and answer engine reach without additional media spend. BRNO, CZ / ACCESS Newswire / January 21, 2026 / As content inventories grow into hundreds of thousands of items, search engine optimization (SEO) has become a significant operational cost. Manual audits, spreadsheet-driven updates, and disconnected tooling make it difficult for teams to keep content accurate, structured, and discoverable across both traditional search engines and AI-driven discovery platforms. Kontent.ai's new agentic workflows are designed to change that cost and effort curve. Embedded directly within the CMS, autonomous agents continuously analyze content for missing or inconsistent metadata, unclear structure, outdated terminology, and weak intern
GA-ASI and Calidus Sign MOU To Collaborate on Co-Production of MQ-9B and Gambit Collaborative Combat Aircraft20.1.2026 18:00:00 CET | Press release
ABU DHABI, UAE / ACCESS Newswire / January 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI), the world leader in unmanned aircraft systems, and Calidus Aerospace, one of the leading defense and manufacturing companies, have signed a Memorandum of Understanding (MOU) to collaborate on the prospective co-production of MQ-9B Remotely Piloted Aircraft and Gambit Collaborative Combat Aircraft (CCA) in the UAE, as well as command and control and battle management systems. The agreement was signed by GA-ASI President David R. Alexander and Dr. Khalifa Murad Alblooshi, Managing Director and CEO of Calidus Holding Group, on the sidelines of the UMEX and SimTEX 2026 taking place January 20-22, 2026. The MOU provides a framework for cooperation between GA-ASI, GA-Intelligence, and Calidus where all parties will look to collaborate on programs in the areas of airframe manufacturing, final assembly, test and checkout, as well as flight operational test and acceptance. "Working with pa
Vossen Capital Management Secures £200 Million in Pre-IPO Investment Commitments20.1.2026 15:20:00 CET | Press release
Vossen Capital Management Ltd ("Vossen Capital" or the "Company"), a specialist investment firm focused on fixed income and private market opportunities, announces that it has secured £200 million in committed capital for its Pre-IPO Investment Programme. LONDON, UK / ACCESS Newswire / January 20, 2026 / Highlights: £200 million committed to Pre-IPO allocations across technology, healthcare, and sustainable infrastructure sectors Expanded institutional partner network providing enhanced deal flow access Strong investor demand driven by track record of successful Pre-IPO placements Programme offers qualified investors early-stage exposure to growth companies ahead of public listings The capital commitments have been secured from a combination of institutional investors, family offices, and high-net-worth individuals seeking exposure to private market opportunities typically reserved for venture capital and institutional funds. Jack Vossen, Head of Private Equity at Vossen Capital, comme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom